ストックスクリーナーアプリを入手
5.20
4.52%
-0.16
前日終値:
$5.36
開ける：
$5.36
24時間の取引高:
516.66K
Relative Volume:
0.52
時価総額：
$492.91M
収益：
-
当期純損益:
$-75.43M
株価収益率:
-4.2619
EPS:
-1.2201
ネットキャッシュフロー:
$-72.75M
1週間 パフォーマンス:
-13.26%
1か月 パフォーマンス:
+50.52%
6か月 パフォーマンス:
-3.07%
1年 パフォーマンス:
+365.25%
1日の値動き範囲:
$4.93
$5.5007
1週間の範囲:
$4.93
$6.01
52週間の値動き範囲:
$1.0804
$7.44
Zura Bio Ltd Stock (ZURA) Company Profile
Compare ZURA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
5.195 | 490.53M | 0 | -75.43M | -72.75M | -1.2201 |
VRTX
Vertex Pharmaceuticals Inc
|
524.43 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
670.63 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
925.67 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
316.84 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.04 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-09 | 開始されました | Wedbush | Outperform |
| 2024-11-04 | 開始されました | Leerink Partners | Outperform |
| 2024-09-05 | 開始されました | H.C. Wainwright | Neutral |
| 2024-05-03 | 開始されました | Piper Sandler | Overweight |
| 2023-10-10 | 開始されました | Ladenburg Thalmann | Buy |
| 2023-08-25 | 開始されました | Oppenheimer | Outperform |
| 2023-06-22 | 開始されました | Guggenheim | Buy |
| 2023-06-14 | 開始されました | Chardan Capital Markets | Buy |
| 2023-05-24 | 開始されました | Raymond James | Strong Buy |
すべてを表示
Zura Bio Ltd (ZURA) 最新ニュース
Zura Bio’s Tibulizumab: First Dual BAFF & IL-17 Bispecific Antibody for Complex Autoimmune Diseases, Advancing in Phase 2 Trials – Minichart - Minichart
Jessica Chen - White & Case LLP
Zura Bio updates corporate presentation; tibulizumab Phase 2 toplines, $225.6M cash (Mar 31, 2026) - TradingView
Zura Bio (NASDAQ: ZURA) furnishes updated corporate presentation for investors - Stock Titan
Guggenheim Maintains Zura Bio(ZURA.US) With Buy Rating, Maintains Target Price $15 - Moomoo
We're Hopeful That Zura Bio (NASDAQ:ZURA) Will Use Its Cash Wisely - simplywall.st
Zura Bio completes enrollment in tibulizumab trials By Investing.com - Investing.com South Africa
ZURA Financial Update: Cash Position and Operational Outlook - GuruFocus
Zura Bio completes Phase 2 trial enrollment for tibulizumab in hidradenitis suppurativa - Traders Union
Zura Bio clears enrollment targets in two Phase 2 studies, adds a third - Stock Titan
Zura Bio Ltd (ZURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Zura Bio (ZURA) VP details share, RSU and option holdings - Stock Titan
Zura Bio | 4: Statement of changes in beneficial ownership of securities-Director Jarrett Jennifer - Moomoo
Zura Bio (NASDAQ: ZURA) director receives grant of 51,000 share options - Stock Titan
Zura Bio (ZURA) director awarded 51,000 share options at $3.62 - Stock Titan
Zura Bio (ZURA) director receives grant of 51,000 stock options - Stock Titan
Zura Bio (ZURA) director Amit Munshi granted 51,000 share options at $3.62 - Stock Titan
Zura Bio (ZURA) director Daniel Becker receives 51,000 share options at $3.62 - Stock Titan
Director at Zura Bio (NASDAQ: ZURA) granted 51,000 stock options - Stock Titan
Zura Bio (ZURA) director receives 51,000 share options at $3.62 strike price - Stock Titan
Zura Bio StockSaturday look at the business model and pipeline - AD HOC NEWS
Zura Bio (NASDAQ: ZURA) investors approve board slate, auditor and 2023 equity plan changes - Stock Titan
Zura Bio Ltd (ZURA) Institutional Confidence - TradingKey
Zura Bio Ltd (ZURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zura Bio Ltd (ZURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zura Bio Ltd (ZURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zura Bio Ltd (ZURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zura Bio Ltd (ZURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Zura Bio Ltd (ZURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zura Bio Ltd (ZURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zura Bio Ltd stock (KYG989201089): Pipeline update and capital raise reshape the story - AD HOC NEWS
Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation - Yahoo Finance
ZURAZura Bio Ltd Stock Price and Quote - Finviz
Zura Bio (NASDAQ: ZURA) discloses resignation of director Someit Sidhu - Stock Titan
Zura Bio Ltd stock (KYG989201089): pipeline update keeps autoimmune story in focus - AD HOC NEWS
Venrock entities report 9.99% ownership in ZURA (ZURA) - Stock Titan
Great Point Partners, Dr. Jay & Nordahl report 4.44% in ZURA (ZURA) - Stock Titan
Zura Bio reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zura Bio stock (KYG989201089): Appoints Muzammil Mustufa as Chief Business Officer - AD HOC NEWS
Zura Bio's new CBO gets options on 600,000 shares at $4.80 - Stock Titan
Zura Bio appoints Muzammil Mustufa as chief business officer By Investing.com - Investing.com Canada
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer - ChartMill
TradingKey - TradingKey
Suvretta/Averill disclose large ZURA stakes (NASDAQ: ZURA) in 13G/A filing - Stock Titan
Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Purchases Worth US$12.5m See Losses As Zura Bio Market Value Drops To US$464m - simplywall.st
Zura Bio Ltd 1Q 2026: Net income $(24.2M), EPS $(0.22) — 10-Q Summary - TradingView
Zura Bio (Nasdaq: ZURA) widens Q1 loss, boosts cash to $225.6M - Stock Titan
Zura Bio (NASDAQ: ZURA) boosts cash with $134.6M raise as R&D loss deepens - Stock Titan
Zura Bio Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates - ChartMill
Zura Bio Ltd (ZURA) 財務データ
収益
当期純利益
現金流量
EPS
1.38%
3.59%
大文字化:
|
ボリューム (24 時間):